|VitamFero||Co-founder, General Manager and VP Business Development||France|
How can animal and human innovation/applications be mutually beneficial?
Co-founder, General Manager and VP Business Development of VitamFero S.A., a French veterinary biotech One Health start-up company located in Angers (France).
Former Key Account Manager, Global Business Development Biotech with SGS Life Science Services (Wavre, Belgium) and former Director, Business Development as well as MEPACT®/Junovan® (product registered in EU by early 2009 and marketed by Takeda/Millennium) Project Leader of IDM S.A. (IDM Pharma Inc. Group), Dr. Breton benefits from a strong 25-year experience in the French and North-American pharmaceutical and biotechnology industry, mostly in R&D and Business Development. Alongside Dr. Nicole Bru, former owner and Chairman of UPSA Laboratories (now part of Bristol-Myers & Squibb, Rueil-Malmaison, France), he notably founded and headed Virsol (Halisol Group, Paris, France), that was focused essentially on developing novel drug delivery systems, biomaterials and medical devices such as a novel surgical adhesive (BondEase®) marketed in the US by Optmed (New York NY). Within the Halisol Group, he was also a Biotech Investment Director and served as a Board Director of companies like Conjuchem Inc. (Montreal), Rimon Therapeutics Ltd. (Toronto), BagTech Corp. (Montreal) or Aarmedis Corp. (Baltimore). Dr. Breton holds a PhD from the University of Orléans, France (1989) and had carried out research for 3 years at the National Institute of Health, USA, as a post-doctoral trainee, and a visiting fellow (1989-1992). Dr. Breton joined the company on a full time basis on January 1st, 2009.